Home › Macular Degeneration › Florida › Orlando
Macular Degeneration clinical trials in Orlando, FL
4 studies for Macular Degeneration are looking for participants at sites in and around Orlando (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
RecruitingPhase 3
- Florida Retina Institute - Orlando, Orlando
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
RecruitingPhase 2/3
- Florida Eye Clinic (Site 130), Altamonte Springs · 9 mi away
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
RecruitingPhase 2
- Florida Retina Institute, Orlando
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
RecruitingPhase 2/3
- Florida Retina Institute, Orlando
About Macular Degeneration
Macular degeneration, or age-related macular degeneration (AMD), is the leading cause of vision loss in older adults. Learn about the types and what might help.
More about Macular Degeneration on MedlinePlus
Macular Degeneration trials in other cities
- Dallas, TX12 studies
- Erie, PA9 studies
- The Woodlands, TX9 studies
- Sacramento, CA7 studies
- Carmel, IN7 studies
- Santa Monica, CA7 studies
- Hagerstown, MD7 studies
- Houston, TX7 studies
- Phoenix, AZ7 studies
- McAllen, TX7 studies
- Cleveland, OH7 studies
- Reno, NV7 studies
Other studies in Orlando
- Non-Small Cell Lung Cancer47 studies
- Obesity33 studies
- Alzheimer's Disease29 studies
- Metastatic Cancer28 studies
- Overweight27 studies
- Type 2 Diabetes25 studies
- Ovarian Cancer24 studies
- Cancer (all types)24 studies
- Breast Cancer23 studies
- Lung Cancer23 studies
- Ulcerative Colitis21 studies
- Colorectal Cancer21 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.